Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

194 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The prediction of human clearance from hepatic microsomal metabolism data.
Obach RS. Obach RS. Curr Opin Drug Discov Devel. 2001 Jan;4(1):36-44. Curr Opin Drug Discov Devel. 2001. PMID: 11727321 Review.
In vitro metabolism of irosustat, a novel steroid sulfatase inhibitor: interspecies comparison, metabolite identification, and metabolic enzyme identification.
Ventura V, Solà J, Celma C, Peraire C, Obach R. Ventura V, et al. Drug Metab Dispos. 2011 Jul;39(7):1235-46. doi: 10.1124/dmd.111.038315. Epub 2011 Apr 4. Drug Metab Dispos. 2011. PMID: 21464173
In vitro evaluation of the interaction potential of irosustat with drug-metabolizing enzymes.
Ventura V, Solà J, Peraire C, Brée F, Obach R. Ventura V, et al. Drug Metab Dispos. 2012 Jul;40(7):1268-78. doi: 10.1124/dmd.111.044271. Epub 2012 Mar 26. Drug Metab Dispos. 2012. PMID: 22451700
Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol.
Obach RS. Obach RS. Drug Metab Dispos. 1997 Dec;25(12):1359-69. Drug Metab Dispos. 1997. PMID: 9394025
Expression and characterization of canine cytochrome P450 2D15.
Roussel F, Duignan DB, Lawton MP, Obach RS, Strick CA, Tweedie DJ. Roussel F, et al. Among authors: obach rs. Arch Biochem Biophys. 1998 Sep 1;357(1):27-36. doi: 10.1006/abbi.1998.0801. Arch Biochem Biophys. 1998. PMID: 9721180
Metabolic characterization of the major human small intestinal cytochrome p450s.
Obach RS, Zhang QY, Dunbar D, Kaminsky LS. Obach RS, et al. Drug Metab Dispos. 2001 Mar;29(3):347-52. Drug Metab Dispos. 2001. PMID: 11181505
(R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes.
Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, Obach RS. Margolis JM, et al. Among authors: obach rs. Drug Metab Dispos. 2000 Oct;28(10):1187-91. Drug Metab Dispos. 2000. PMID: 10997938
Pharmacokinetics of ezlopitant, a novel non-peptidic neurokinin-1 receptor antagonist in preclinical species and metabolite kinetics of the pharmacologically active metabolites.
Reed-Hagen AE, Tsuchiya M, Shimada K, Wentland JA, Obach RS. Reed-Hagen AE, et al. Among authors: obach rs. Biopharm Drug Dispos. 1999 Dec;20(9):429-39. doi: 10.1002/1099-081x(199912)20:9<429::aid-bdd209>3.0.co;2-d. Biopharm Drug Dispos. 1999. PMID: 10951432
Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation.
Obach RS. Obach RS. Drug Metab Dispos. 2000 Sep;28(9):1069-76. Drug Metab Dispos. 2000. PMID: 10950851
Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression.
Obach RS. Obach RS. J Pharmacol Exp Ther. 2000 Jul;294(1):88-95. J Pharmacol Exp Ther. 2000. PMID: 10871299
194 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback